Education
About Us
Working with TipRanks
Follow Us
Geovax Labs, Inc. (GOVX)
:GOVX
Top Page
GeoVax Labs
(NASDAQ:GOVX)
Rating:34Underperform
Price Target:―
Positive Factors
Clinical Studies
Additional data announcements from clinical studies with 04S1 could be positive catalysts through 2025.
Comparative Analysis
DSMB Review Suggests GEO-CM04S1 May Be Superior to mRNA Vaccine.
Vaccine Development
GEO-CM04S1 booster studies to continue, with early clinical studies showing the vaccine induces durable neutralizing antibody and T-cell-based immunity against current and future variants of SARS-CoV-2.
Negative Factors
Contract Termination
Termination of the contract will not have a long-term material effect.
Project Termination
GeoVax Labs announced it received written notification from Advanced Technology International directing GeoVax to stop work on all efforts with respect to a Rapid Response Partnership Vehicle project.
GeoVax Labs (GOVX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$18.49M
Dividend YieldN/A
Average Volume (3M)2.21M
Price to Earnings (P/E)―
Beta (1Y)2.87
Revenue GrowthN/A
EPS Growth71.39%
CountryUS
Employees17
SectorHealthcare
Sector Strength38
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.35
Shares Outstanding25,359,592
10 Day Avg. Volume1,214,207
30 Day Avg. Volume2,214,163
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.55
Enterprise Value/Revenue1.93
Enterprise Value/Gross Profit1.94
Enterprise Value/Ebitda-0.41
Forecast
1Y Price Target
$10.83Price Target Upside1383.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
GeoVax Labs Business Overview & Revenue Model
Company DescriptionGeoVax Labs (GOVX) is a biotechnology company specializing in developing human vaccines. The company's primary focus is on creating vaccines for infectious diseases, cancer immunotherapy, and other novel treatments by utilizing their innovative MVA-VLP vaccine platform. GeoVax leverages its expertise in vaccine development to address global health challenges, aiming to provide solutions for diseases such as HIV, Zika, Lassa fever, Ebola, and COVID-19.
How the Company Makes MoneyGeoVax Labs generates revenue through a combination of government and non-governmental grants, collaborative research and development agreements, and potential licensing deals. The company partners with various organizations and institutions to advance its vaccine candidates, often receiving funding and milestone payments in return. GeoVax also seeks to monetize its vaccine platform through licensing agreements with other biotech or pharmaceutical companies, allowing them to use the technology for their own product development. Revenue may also be derived from future product sales as vaccines progress through clinical trials and achieve regulatory approval.
GeoVax Labs Earnings Call Summary
Earnings Call Date:Aug 06, 2025
(Q2-2025)
| % Change Since: -26.26%|
Next Earnings Date:Nov 06, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mixed picture. Significant achievements included the EMA's expedited path for GEO-MVA, increased revenues, and progress in vaccine development. However, these were offset by the termination of the BARDA contract, increased expenses, and continued net losses, leading to balanced highlights and lowlights.Q2-2025 Updates
Positive Updates
EMA Guidance for GEO-MVA
GeoVax received guidance from the European Medicines Agency (EMA) for an expedited development path for GEO-MVA, allowing them to bypass Phase I and II trials and proceed directly to a Phase III immunobridging trial.
Increased Revenue
GeoVax reported revenues of $2.5 million for the first six months of 2025, a significant increase from $301,000 in 2024.
GEO-CMO4S1 Progress
The company is advancing its GEO-CMO4S1 vaccine for immunocompromised patients, with multiple ongoing clinical trials and presentations at major conferences.
Gedeptin Phase II Study
Plans are underway for a Phase II Gedeptin trial in head and neck cancer, with protocol modifications based on recent KEYNOTE-689 study results.
Follow-on Public Offering
GeoVax concluded a follow-on public offering in July, raising almost $6 million in net proceeds, bolstering cash balances.
Negative Updates
BARDA Contract Termination
The BARDA project NextGen contract, which began in June 2024, was terminated as part of the government's efficiency program, impacting future revenues.
Increased Expenses
Research and development expenses increased by 16% to $10 million, and general and administrative expenses increased by 27% to $3.2 million, primarily due to higher investor relations consulting costs and stock-based compensation.
Cash Flow and Losses
The company reported a net loss of $10.7 million for the six-month period in 2025, with cash balances decreasing to $3.1 million from $5.5 million at the end of 2024.
Company Guidance
In the GeoVax Second Quarter 2025 Corporate Update Call, the company provided guidance on several key metrics and developments. GeoVax received guidance from the European Medicines Agency (EMA) to expedite the development of its GEO-MVA vaccine candidate, allowing the bypass of Phase I and Phase II trials to proceed directly to a Phase III immunobridging trial. This potentially accelerates marketing authorization and revenue generation. The company also discussed its GEO-CMO4S1 COVID-19 vaccine, emphasizing its importance for over 40 million immunocompromised adults in the U.S. and 400 million worldwide, citing a robust immune response against emerging variants. Additionally, GeoVax outlined plans for a Phase II Gedeptin trial in head and neck cancer, with a primary endpoint focusing on major pathological response, expecting to initiate the trial in the second half of 2026. Financially, GeoVax reported revenues of $2.5 million for the first half of 2025, an increase from $301,000 in 2024, and a net loss of $10.7 million compared to $10.9 million in the prior year, with cash balances of $3.1 million as of June 30, 2025.GeoVax Labs Financial Statement Overview
Summary
GeoVax Labs faces significant financial challenges with no revenue growth and continuous net losses, reflecting operational and market difficulties. The company's strong cash position offsets some risks, but negative cash flows and reliance on financing indicate potential financial instability.Income Statement
GeoVax Labs has consistently reported zero or negligible revenue, indicating a significant challenge in generating sales. The company has experienced persistent net losses with negative EBIT and EBITDA margins, reflecting operational inefficiencies and high costs relative to its revenue base.10
Very Negative
Balance Sheet
The balance sheet shows a relatively strong cash position with no debt, which is a positive sign of financial prudence. However, the equity ratio is weak due to a low level of total assets and historical negative equity, posing risks to financial stability and growth potential.25
Negative
Cash Flow
GeoVax Labs exhibits negative operating and free cash flow, indicating potential cash management issues. The company relies heavily on financing activities to support its operations, raising concerns about sustainability and the need for continued external funding.15
Very Negative
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.95M | 0.00 | 81.00K | 385.00K | 1.82M |
| Gross Profit | 3.86M | -20.72M | 24.72K | -15.17M | -621.46K |
| EBITDA | -24.88M | -26.67M | -13.97M | -18.53M | -2.79M |
| Net Income | -24.99M | -25.97M | -14.01M | -18.53M | -2.94M |
Balance Sheet | |||||
| Total Assets | 8.16M | 9.28M | 31.35M | 11.80M | 10.39M |
| Cash, Cash Equivalents and Short-Term Investments | 5.51M | 6.45M | 27.61M | 11.42M | 9.88M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 198.06K |
| Total Liabilities | 3.11M | 3.52M | 4.75M | 7.43M | 825.00K |
| Stockholders Equity | 5.05T | 5.76M | 26.60M | 4.36M | 9.57M |
Cash Flow | |||||
| Free Cash Flow | -24.70M | -25.22M | -19.16M | -11.24M | -2.91M |
| Operating Cash Flow | -24.68M | -25.17M | -19.03M | -11.20M | -2.75M |
| Investing Cash Flow | -20.65K | -48.95K | -134.26K | -47.72K | -156.79K |
| Financing Cash Flow | 23.75M | 4.06M | 35.35M | 12.78M | 12.51M |
GeoVax Labs Technical Analysis
Negative
0.73
Price Trends
0.87
Negative
0.97
Negative
1.55
Negative
Market Momentum
-0.02
Negative
45.60
Neutral
28.82
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GOVX, the sentiment is Negative. The current price of 0.73 is below the 20-day moving average (MA) of 0.74, below the 50-day MA of 0.87, and below the 200-day MA of 1.55, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 45.60 is Neutral, neither overbought nor oversold. The STOCH value of 28.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GOVX.
GeoVax Labs Risk Analysis
GeoVax Labs disclosed 31 risk factors in its most recent earnings report. GeoVax Labs reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
GeoVax Labs Peers Comparison
Overall Rating
UnderperformOutperform
Sector (63)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | €5.97B | 18.62 | -1.87% | 2.13% | 0.91% | -39.98% | |
49 Neutral | $13.23M | 0.71 | -162.42% | ― | -82.24% | ― | |
44 Neutral | $20.68M | ― | -214.79% | ― | ― | 52.82% | |
43 Neutral | $50.94M | ― | -27.00% | ― | 1904.43% | 93.72% | |
42 Neutral | $11.28M | ― | -76.12% | ― | ― | 81.71% | |
40 Underperform | $10.39M | ― | -64.18% | ― | ― | 1.00% | |
34 Underperform | $18.49M | ― | -9690.24% | ― | ― | 71.39% |
* Healthcare Sector Average
Performance Comparison
GOVX
GeoVax Labs
0.73
-1.05
-58.99%
PHIO
Phio Pharmaceuticals
2.35
-0.39
-14.23%
MBRX
Moleculin Biotech
0.68
-1.52
-69.09%
ABVC
ABVC BioPharma
3.00
2.33
347.76%
ADXN
Addex Therapeutics
8.13
0.62
8.26%
SNSE
Sensei Biotherapeutics
8.24
-4.45
-35.07%
GeoVax Labs Corporate Events
Product-Related AnnouncementsBusiness Operations and Strategy
GeoVax Labs Faces Contract Termination for COVID-19 Vaccine
Negative
Apr 14, 2025
On April 11, 2025, GeoVax Labs received a notification from Advanced Technology International to halt work on a Phase 2B clinical trial for their GEO-CM04S1 COVID-19 vaccine. The termination of the contract was decided by BARDA for governmental convenience, impacting the company’s ongoing project and possibly its strategic positioning in vaccine development.
Spark’s Take on GOVX Stock
According to Spark, TipRanks’ AI Analyst, GOVX is a Underperform.
GeoVax Labs is navigating substantial financial and operational challenges. While the BARDA award and vaccine advancements are significant positives, the company’s financial instability, negative cash flow, and bearish technical indicators weigh heavily on its overall score. The mixed sentiment from the earnings call, highlighting both achievements and setbacks, contributes to a cautious outlook.
To see Spark’s full report on GOVX stock, click here.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.